Highlights

  • Memphasys identifies a potential change in its US regulatory pathway for the Felix Sperm Separation System.
  • The company points to a predicate device that could support an FDA 510(k) clearance route.
  • New figures highlight the scale of the US assisted reproductive technology market.
  • A Pre-Submission engagement with the FDA is planned ahead of a targeted 2027 filing.

Memphasys Limited (ASX:MEM) has revised its approach to bringing its Felix Sperm Separation System to the United States, after its board identified a route to regulatory clearance that could prove faster and less costly than the pathway previously under consideration. The ASX-listed reproductive health company said it now sees potential for a more direct route to approval from the US Food and Drug Administration, a development that could reshape the timeline for its US market entry.

Felix is designed to separate sperm for use in assisted reproductive technology procedures, and its performance in that process is central to how fertility clinics assess and adopt new laboratory equipment. Memphasys had originally been planning to pursue the FDA's De Novo classification pathway, a route typically used for novel medical devices that do not have a direct predecessor already cleared for sale in the US market. The company has since identified an existing predicate device that may allow Felix to instead pursue the FDA's 510(k) clearance pathway, a process built around demonstrating that a new device is substantially equivalent to one already legally marketed in the United States.

A More Direct Route to FDA Clearance

The distinction between the two regulatory pathways matters for how quickly, and at what cost, a medical device company can bring a product to market. The De Novo pathway is generally used for products that introduce new technology without a comparable device already available, and it typically involves a more extensive review process along with broader evidence requirements and longer regulatory timeframes. The 510(k) pathway, by contrast, allows a company to reference an already-cleared predicate device and to focus its submission on demonstrating that the new product shares the same intended use and technological characteristics, or that any differences do not raise new questions about safety or effectiveness.

For a company preparing to enter one of the world's largest fertility markets, moving to a pathway that has historically involved shorter review periods and a reduced testing burden could translate into an earlier commercial launch and lower overall regulatory costs. Memphasys said the reassessment reflected ongoing engagement with US regulatory requirements and a closer review of comparable devices already cleared for the American market. Identifying a workable predicate is a critical step in any 510(k) submission, since the clearance argument rests on demonstrating the new device's similarity to that reference product rather than establishing an entirely new product category from first principles.

Sizing the US IVF Opportunity

The strategic shift comes as Memphasys continues to weigh the commercial scale of the US fertility market against its regulatory options. Approximately 500 clinics across the United States provide assisted reproductive technology services, and CDC data cited by the company recorded 435,426 ART cycles across 457 reporting clinics in 2022. ART cycles refer to fertility treatments in which both eggs and sperm are handled outside the body, the category of procedure into which Felix's sperm separation technology is designed to fit.

The company said the US IVF market was valued at approximately US$5.9 billion in 2025, representing roughly 20% of the global IVF market by revenue. That places the United States among the largest single-country fertility markets in the world, and underlines why the company continues to prioritise a US regulatory pathway even as it already commercialises Felix in other regions. A faster route to clearance would allow Memphasys to pursue this market opportunity sooner than under its original regulatory plan, without altering the underlying scale or structure of the US ART sector described in these figures. A device used within even a modest share of the roughly 500 clinics offering assisted reproductive technology services in the United States would represent a meaningful expansion of Felix's addressable market relative to the regions in which it is currently sold.

Next Steps and Parallel Commercialisation

Memphasys plans to engage the FDA through a Pre-Submission process, often referred to as a Q-Submission, before lodging a formal application. This mechanism allows a company to present its proposed predicate device, regulatory strategy and supporting evidence to the FDA and receive feedback ahead of a formal filing, which can reduce the risk of delays or requests for additional information once the official 510(k) submission is lodged. Engaging with the regulator at this preliminary stage is a widely used step for medical device companies, since it allows any concerns about the proposed predicate or supporting evidence to be identified and addressed before a formal application clock begins to run. Memphasys is targeting a formal 510(k) submission in the first quarter of 2027, following completion of this preliminary engagement.

The company said the US regulatory program will proceed in parallel with its existing commercialisation efforts across Europe, Australia, New Zealand, Asia and the Middle East and North Africa region, where Felix is already sold through distributor partnerships. Memphasys continues to expand its distributor network in these established markets and reported receiving repeat orders from existing partners, an indicator of ongoing product usage in clinics that have already adopted the system. The company said the US strategy adjustment does not affect these existing commercial arrangements, with the FDA engagement instead adding a further potential market to the company's international footprint over time.

Key Insights

The announcement centres on a change in regulatory strategy rather than a change in product design, with Memphasys pointing to a predicate device that could allow Felix to pursue the FDA's 510(k) clearance pathway instead of the previously contemplated De Novo route. This shift, if borne out through the planned Pre-Submission engagement, could affect the timeline for the company's entry into the US fertility market, which the company describes as a multi-billion-dollar sector by revenue. Importantly, the company has framed the US regulatory work as running in parallel with, rather than instead of, its established commercialisation activities in Europe, Australia, New Zealand, Asia and the MENA region, where distributor relationships and repeat orders continue. The formal 510(k) submission remains targeted for the first quarter of 2027, subject to feedback from the FDA during the preliminary engagement process.